Mobile

A randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab versus adalimumab, both in combination with MTX, in patients with moderate to ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-023587-40

A randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab versus adalimumab, both in combination with MTX, in patients with moderate to severe active rheumatoid arthritis and an inadequate response to treatment with only one TNF inhibitor

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the efficacy of treatment with tocilizumab (TCZ) 8 mg/kg intravenously (iv) (every 4 weeks) versus adalimumab (ADA) 40 mg subcutaneously (sc) (every 2 weeks), both in combination with methotrexate (MTX), with regard to achievement of clinical remission as measured by Disease Activity Score 28 (DAS28) <2.6 at the end of 24 weeks of treatment in patients with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate efficacy response to treatment with only one tumor necrosis factor (TNF) inhibitor (other than ADA).

Critère d'inclusion

  • Adult Rheumatoid Arthritis (RA)

Liens